A Study of CS23546 in Subjects With Advanced Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Tumors

In brief

The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.

Key facts

Study ID

NCT06245122

Run by

Chipscreen Biosciences, Ltd.

People needed

156

Starts

2024-03-27

Expected to finish

2027-05-31

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sun Yat-sen University Cancer Cancer — Guangzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.